RxDoctor Payments Data

Marla Torres Torres

Colon & Rectal Surgery · San Juan, PRNPI 1770762585

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (40.5%), speaking fees and education — rather than concentrated in one kind of arrangement. 8 manufacturers reported payments, led by Stryker at 38.6% of the total. Reporting peaked in 2019 at $25,292 and has fallen 96.0% since, to $1,001 in 2025.

$41,693in general payments, 2019–2025

Across 120 payments — averaging $347.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Stryker$16K
  • Medtronic$12K
  • Intuitive Surgical$11K
  • AbbVie$2K
  • Boehringer Ingelheim$297
  • Johnson And Johnson International$101
  • plus $112 from 2 others

What the payments were for

  • Consulting fees$16,88540%
  • Speaking & faculty fees$9,35022%
  • Travel & lodging$4,00510%
  • Food & beverage$2,9537%
  • Education$8,50020%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Stryker19$16,091
Medtronic(2 entities)62$12,195
Intuitive Surgical17$11,259
AbbVie5$1,638
Boehringer Ingelheim12$297
Johnson And Johnson International1$101
Johnson & Johnson3$92
Pfizer Pharmaceuticals LLC1$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few colon & rectal surgery providers in Puerto Ricoto place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$51,387
Medicare patients
81
Services billed
270

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide103$58,444
Mesalamine39$8,966
Dexlansoprazole DrDexlansoprazole22$4,691
CholestyramineCholestyramine (With Sugar)51$3,419
DexilantDexlansoprazole11$3,411
Sucralfate61$3,171
Naloxone Hcl186$2,132
LoperamideLoperamide Hcl46$2,057
Cholestyramine LightCholestyramine22$1,806
SuprepSodium, Potassium,mag Sulfates12$1,409
Lubiprostone11$1,253
Nystatin37$937
Hydrocortisone26$817
Pantoprazole Sodium97$735
Procto-Med HcHydrocortisone22$675

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$1,638$58,444103 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few colon & rectal surgery providers in Puerto Ricoon file to place this against a meaningful peer group, so we don't.

Other colon & rectal surgery in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →